Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial

Inclusion Criteria: * patients with type 2 diabetes mellitus ; * Aged: 55 - 75 years ; * Cognitive function assessment suggests mild cognitive impairment; * A stable glucose-lowering regimen include Metformin alone or in combination with antidiabetic drugs other than SGLT2 inhibitors or sulfonylureas/glinides, or basic insulin for more than 2 months, and the dose of metformin≥1.0g/d; * HbA1c: 7 - 10%; * ≥6 years of education; * Right-handed. Exclusion Criteria: * Cognitive function assessment suggests normal cognition or dementia; * Other dementia related neurological diseases or depression, Mental dysplasia, mania, schizophrenia, etc in the past 2 years; Central nervous system diseases, including brain trauma, intracranial hemorrhage, acute cerebral infarction, etc; * Severe sinusitis, nasal cavity and sinus polyps, skull base or nasopharyngeal tumors and other space occupying lesions; * Congenital diseases and traumatic history of nose, maxillofacial and skull base affecting olfaction. * With symptoms of upper respiratory tract infection, including nasal congestion, runny nose, fever, etc. on the day of MR examination; * Diabetic Acute and chronic complications, including diabetic ketoacidosis, diabetic ketoacidosis; a hyperglycemic hyperosmolar state or severe hypoglycemic coma, etc. * Severe impairment of heart, liver, kidney and other organs; * Contraindications of MRI examination, such as implantation of metal prosthesis in vivo, claustrophobia, etc; * Pregnant and l…